4D Molecular Insider Sale Shows CEO Confidence, Not a Warning
4D Molecular Therapeutics insider sale: CEO David Kirn sells 1,922 shares via a 10(b)(5)(1) plan at $10.02—showing confidence while keeping long‑term stake.
- 4D MOLECULAR THERAPEUTICS IN
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read